Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biodesix (BDSX) Shares Outstanding (2019 - 2026)

Biodesix filings provide 8 years of Shares Outstanding readings, the most recent being $10.1 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 38.04% to $10.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.1 million, a 38.04% increase, with the full-year FY2025 number at $8.3 million, up 13.44% from a year prior.
  • Shares Outstanding hit $10.1 million in Q1 2026 for Biodesix, up from $8.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $88.3 million in Q3 2023 to a low of $4.8 million in Q4 2023.
  • Median Shares Outstanding over the past 5 years was $8.3 million (2025), compared with a mean of $29.9 million.
  • Biggest five-year swings in Shares Outstanding: surged 152327.83% in 2022 and later plummeted 93.8% in 2023.
  • Biodesix's Shares Outstanding stood at $77.6 million in 2022, then plummeted by 93.8% to $4.8 million in 2023, then soared by 51.18% to $7.3 million in 2024, then grew by 13.44% to $8.3 million in 2025, then grew by 22.47% to $10.1 million in 2026.
  • The last three reported values for Shares Outstanding were $10.1 million (Q1 2026), $8.3 million (Q4 2025), and $8.0 million (Q3 2025) per Business Quant data.